Theranostics Nanomedicine: Recent Advancement, Applications and Challenges

Shailesh Ghaywat a, Payal Dhande a, Sneha Gaurkar a, Samiksha Upadhyay a, Vaishnavi Raut a, Neha Binjhade a, Kamlesh Wadher a* and Milind Umekar a

a Department of Pharmaceutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34927

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/79894

Received 18 October 2021
Accepted 22 December 2021
Published 26 December 2021

ABSTRACT

Many advancements have been made in treatment and diagnosis tools with the progress in modern medicine and technology. Theranostics are multifunctional nanomaterials that combine therapeutic as well as imaging functions. Theranostic nanomedicines are used for checking drug release and efficacy. The amalgamation of diagnostic and therapeutic agents within a single system provides the target site localization and accumulation of nanomedicines in organs. It provides a transition from conventional medicine to personalized medicine. Many different types of nanomedicines have been evaluated over the years. Theranostics approach includes pharmacogenomics, personalized medicine and imaging to develop efficient new targeted therapies which will help in better and optimize drug selection along with monitoring the therapy response to increase drug safety and efficacy. This review summarizes the recent development and various nanocarriers developed for nanotheranostics, includes inorganic Nanoparticles, Polymeric, dendrimers, micelles, liposomes, metallic, and carbon nanotubes.

Keywords: Theranostics; nanomedicine; nanoparticles; personalized therapy; liposomes; targeting.

*Corresponding author: E-mail: kamleshwadher@gmail.com;
1. INTRODUCTION

The past decade witnessed a tremendous progress in the field of diagnostics and treatments due to the advancement in medicinal and pharmaceutical area. Theranostic is an emerging therapeutic system which combines therapy and diagnostic strategy in a nanostructure entity for developing targeted personalized therapy [1]. Theranostic obtained when a single particle (nanoparticle), is fabricated which contain a combination of therapeutic element (drug) and diagnostic/imaging element. In the scientist community, there is increase in the interest for theranostic drug delivery systems for the management of diseases such as, inflammatory and cancer [2]. Recent Innovations in nano delivery system have led to the escalating research work and advancement on nanotheranostics due to various advantages of nanoparticles such as site-specific targeting, thermo stimulation, phototherapy and delivery of combination of drugs [1]. There are various diagnostic/imaging agents utilized in Theranostic nano carriers such as quantum dots, fluorescent dyes and superparamagnetic iron oxides for optical imaging, magnetic resonance imaging (MRI), nuclear imaging and computed tomography [3]. For theranostic applications, various combinations of therapeutic and imaging combinations are possible.

Several drug delivery systems reported to use clinically such as, liposomes, micelles and nanoparticles etc. [4,5]. Therapeutics along with the Imaging agents generally added in to into nanocarrier system, with the aim to provide diagnostic information and thus utilize as theranostic agents which help to observe drug release as well as drug efficacy [1]. In the present Review article, we discussed the possible use of nanocarrier system for drug delivery and imaging purposes, along with the recent applications and challenges of Theranostics in Pharmaceutical drug delivery development.

2. THERANOSTIC NANOMEDICINE

Due to multifunctional and intrinsic molecular characteristics, nanomaterials have emerged as one of the promising tool in theranostics and biomedical science [6-8]. The variety of Theranostic platforms are explored such as in therapy, formulation design, diagnostics, imaging, drug delivery. Also, utilization for the diagnosis and treatment of many diseases including Inflammations, cardiovascular diseases, diabetes and cancer are shown in Fig 1.

With the advancement of technology, Nanotheranostics have been developed for checking release, distribution and efficacy of drug through a single nanocarrier system for precise detection and therapy [9-17]. Many researchers worked on nanoparticle based theranostic agents have such as, magnetic, gold, silica Nanoparticles, carbon nanotubes and quantum dots [18-22].

Theranostics nanoparticles are mainly composed of polymeric, lipid based and metallic nanomaterials such as, organic and inorganic materials, nano capsules, micelles, liposomes, dendrimers, quantum dots, and carbon nanotubes as depicted in Fig. 2.

Fig. 1. Theranostic platform and applications in various disease and disorders
2.1 Metallic Nanoparticles for Theranostics

Organic and inorganic nanoparticle used includes, gold, Silver and iron oxides.

2.1.1 Gold nanoparticles

Gold Nanoparticles (AuNPs) are biocompatible, possess excellent physical and chemical properties, prepared as cubes, spheres, rods, and cages and act as a promising agents in terms of both imaging and therapy [23-26]. AuNPs offer the advantage of fictionalization with drugs through covalent and ionic binding and useful for biomedical applications, specially on treatment of cancer. On account of its optical properties AuNPs act as an NIR-active imaging probe for cancer detection facilitating scanning of whole body. AuNPs showed promising results in treating MDR tumors by combining chemotherapeutic agent and photothermal treatment [27-30]. Functionalized AuNPs have wide applications in drug delivery, biological detection, clinical treatment and also reported to be efficient and improve the treatment of gliomas [31,32]. Recently, matrix metalloproteinase-2- sensitive gold-gelatin nanoparticles were developed to pass through the BBB, allowing a pH-triggered release to the glialoma specific area [33].

2.1.2 Silver nanoparticle

Silver nanoparticles (AgNPs) have unique characteristics that make them ideal for cancer diagnosis and therapy and reported to involved in biomedical applications such as drug delivery vectors and theranostics agents [33,34]. Many researchers have worked on preparation of silver nanocomposite particles for cancer theranostics [35] Many researchers worked on and developed AgNPs that showed anticancer activity against different cancer cells, as AgNPs modified by luminescent Ru(ii) complexes can target lysosomes Ru1-2 and can act as a potential theranostic agent [35,36].

2.2 Polymer Based Nanoparticles

Nanoparticulated polymer based systems proven to improve therapeutic efficacy and diagnosis sensitivity. Polymeric Nanoparticles prepared from poly(lactic acid)/poly(lactic-co-glycolic acid) PLA/PGLA,block copolymers, and chitosan are utilized in Theranostics due to their biocompatibility, better physiochemical characteristics, nontoxicity and storage stability [37,38]. Fluorescent polymeric nanoparticles (FNPs) were researched as theranostic agents for cancer detection and treatment [39,40].

Polymer based magnetic nanoparticles (PMNPs) have applications in targeted drug delivery, cell tracking, tissue engineering and bio separation and found to be an efficient nanotheranaostic system for diagnostics as well as drug delivery [41,42]. Dendrimers, highly branched macromolecules have found
many applications in theranostic nanomedicine. Many researchers have developed dendrimers for cancer theranostics [43].

2.2.1 Drug-polymer conjugates

Conjugated polymer nanomaterials (CPNs), found to be promising theranostic agent as it possesses both optically and electronically properties. CPNs include protein conjugates and drug conjugates with appropriate polymers and are used for theranostics because of high stability, non-toxic and biocompatible nature [44, 45]. These are easy to prepare, tunable in their size, and nonbleach able which makes ideal for for biomedical fluorescence and photoacoustic imaging as well as for theranostic applications [46] Yuan et al synthesized poly(HPMA) based theranostic copolymers loaded with Cu-64 and used as targeting ligand for targeting tumor angiogenesis [47].

2.2.2 Chitosan nanoparticles

Several researchers have conducted studies on chitosan Nanoparticles (CNPs) for CANCER drug delivery. CNPs generally used for a disease specific theranostic delivery system of different imaging agents and therapeutics CNPs also used as co delivery strategies in combination with diagnostics and image guided therapy to improve therapeutic effects [48]. CNPs developed as theranostic agents because of their good loading capability, biodegradability, biocompatibility, biodegradability and physiological stability.

Loutfy et al. synthesized CNPs for evaluation of the in vitro human carcinoma cell model (HepG2) and reported that, CS-NPs are suitable for drug delivery proposes for cancer of the liver [49].

2.3 Lipid Based Nanoparticles

lipid-based nanocarrier (LNPs) because of their biocompatibility, biodegradability, structural simplicity, found to be safe and easy for manufacturing for cancer theranostics. Bondi et al., (2015) prepared LNPs for the controlled release of sorafenib. And found that, these nanocarrier can be a good delivery agent for liver cancer [50]. Zhao et al., (2015) developed doxorubicin and curcumin LNPs and reported to have excellent inhibitory effect on tumor growth [51].

2.3.1 Solid lipid nanoparticles (SLN)

The solid lipid nanoparticles (SLNs) consist of drug along with solid lipids, surfactants/co-surfactant and explored by many researchers for use in cancer Theranostics [52]. SLNs due to their small size and lipophilic surface gets easy access to the blood compartment to cross tight-endothelial cells of barrier for brain targeting. Kuang et al developed IR-780 iodide loaded tumor vasculature targeted SLNs to monitor PTT by imaging at glioblastoma tissue [53-55]. Bae et al. reported quantum dots loaded SLN for anticancer theranostics [56]. Videira, MA prepared and studied lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles [57].

2.3.2 Liposomes

Liposomes used as a nanocarriers for the delivery of many drugs and diagnostic agents are most popular because of biocompatibility, biodegradability and their surfaces properties can also be modified for use in cancer targeting [58,59]. The liposomes can successfully protect the functional components from the external environment, prolong the systematic circulation time, and enhance their tumor accumulations [58]. Many researchers have worked on liposomal formulations that have applications in targeting, therapeutic, and imaging functionalities. Liposomes have capability to encapsulate diagnostic and therapeutic agents which ultimately led to utilizing liposomes as nanocarriers for theragnostic applications. liposomes as nanocarriers is used for theranostic applications such as for simultaneous detection and treatment of heavy metal toxicity and cancers. Hybrid liposomes (HL) reported to have ability to detect tumors in an orthotopic graft model mouse of breast cancer which found to have theranostic significance in patients with breast cancer [60-66].

2.3.3 Micelles

Polymeric micelles are self-assembling colloidal structure with a hydrophobic core and hydrophilic shell and used theranostic carriers and imaging probes [67]. Therapeutic/ diagnostic agents is loaded into hydrophobic core of micelles and also the outer hydrophilic layer with targeting agent, which might then be administered intravenously. Kumar R et al, Synthesized phospholipid based micellar system
encapsulating QDs/doxorubicin and showed a sustained release from the micellar core over a period of 7 days [68-71].

2.3.4 Dendrimers

Dendrimers are branched nano delivery with controlled functionality and efficiently tailored for the spatial distribution of varied functionalities on their surface. These versatile functions, which permit stimuli–response ability and also the ability to self-assembly, make dendrimers excellent candidates for theranostic applications [72]. Sk UH et al, discussed the in vitro and in vivo applications of dendrimers in many diseases including cancer and explored its use as imaging agents for fluorescence imaging and magnetic resonance imaging [73]. Saad and coworker designed, and evaluated a theranostic dendrimer to deliver paclitaxel and diagnostic agent [74]. Taratula et al. developed a novel dendrimer based theranostic platform for tumor- targeted delivery of phthalocyanines. Which revealed the significant potential of dendrimers as an efficient theranostic agent [75].

2.4 Carbon Nanomaterials

2.4.1 Nano carbons

Nano carbons, such as carbon nanotubes (CNTs), graphene derivatives and carbon dots (C-dots) possess inherent optical properties which makes them useful contrast agents in optical imaging and sensing [76-78] CNTs are useful for theranostic applications since they improve the effect of chemotherapeutic drugs and are adaptable to clinical applications [86-88]. Chen et al., reviewed the applications of functionalized fullerenes in tumor theranostics [89]. Xu and co-workers investigated the influence of oxidized multiwalled CNTs on macrophages and in cancer immunotherapy [90]. Shen H and co-workers reported the applications of graphene and graphene derivatives in drug and gene delivery, cancer therapy, biomedical imaging, biosensing and tissue engineering [91].

3. RECENT ADVANCEMENT OF THERANOSTIC NANOPARTICLES

The Table 1 summarized the recent applications and advancement of Theranostic Nanoparticles

| Types of theranostic nanomaterials | Theranostic advancement | References |
|-----------------------------------|-------------------------|------------|
| Liposomes                         | Targeting and Imaging   | [79]       |
| Gold Nanoparticles                | Improve the treatment of Cancer | [80]       |
|                                   | Stimulus responsive drug release | [81]       |
| Magnetic Nanoparticles            | Increase accumulation in brain tumors | [82]       |
| Drug-polymer conjugates           | Cancer imaging and radio chemotherapy | [47]       |
| Solid lipid Nanoparticles         | Multimodal Therapy      | [83]       |
| Polymeric nanoparticles           | Therapeutic efficacy and diagnosis sensitivity | [84]       |
| Dendrimers                        | Stimuli–response ability | [75]       |
| Micelles                          | Delivery of single theranostic agent | [85]       |
| Carbon Nanotubes                  | Improve the effect of chemotherapeutic agent and translatable to clinical application | [86,87]   |
| Carbon nanomaterials              | Self-photoluminescent and photothermal property | [88]       |
4. CHALLENGES

The challenges associated with theranostic nanomedicine are interaction and compatibility between nano material and biological components which shows immunoreactions and inflammation along with the safety profile in humans [92]. The major challenge associated with thetheranostic nanomedicines is the difficulty in control and reproducibility of the formulation process. Since theranostic nanoparticles are multifunctional unit, more accurate formulation approach and control along with good manufacturing practice are needed [93]. Also, more stringent regulatory steps are needed to bring theranostic nanomedicine from research lab to clinical use.

5. CONCLUSION

Nano theranostics is a field that conglomerates the merits of diagnosis and therapy. Theronostics not only takes advantages to deliver the drug but also useful in imaging and diagnose functions. The NP based theranostic involves gold, magnetic, carbon nanotube, etc. and have shown potential outcome in cancer and other diseases.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44(10):1029-38. DOI: 10.1021/ar200019c.
2. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatorms for simultaneous cancer imaging and therapy: Current approaches and future perspectives. Nanoscale. 2012;4(2):330-42. DOI: 10.1039/c1nr11277e.
3. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011;1:102-26. DOI: 10.7150/thno/v01p0102.
4. Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: The end of the beginning. Adv Drug Deliv Rev. 2013;65(1):60-70. DOI: 10.1016/j.addr.2012.08.012.
5. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48. DOI: 10.1016/j.addr.2012.09.037.
6. Mukherjee S, Patra CR. Therapeutic application of anti-angiogenic nanomaterials in cancers. Nanoscale. 2016;8(25):12444-70. DOI: 10.1039/c5nr07887c.
7. Yue X, Dai Z. Liposomal Nanotechnology for Cancer Theranostics. Curr Med Chem. 2018;25(12):1397-1408. DOI:10.2174/0929867324666170306105350.
8. Mukherjee A, Paul M, Mukherjee S. Recent Progress in the Theranostics Application of Nanomedicine in Lung Cancer. Cancers (Basel). 2019;11(5):597. DOI:10.3390/cancers11050597.
9. Zhu L, Zhou Z, Mao H, Yang L. Magnetic nanoparticles for precision oncology: Theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine (Lond). 2017;12(1):73-87. DOI:10.2217/nnm-2016-0316.
10. Jiang B, Fang L, Wu K, Yan X, Fan K. Ferritins as natural and artificial nanozymes for theranostics. Theranostics. 2020;10(2):687-706. DOI: 10.7150/thno.39827.
11. Sneider A, VanDyke D, Paliwal S, Rai P. Remotely Triggered Nano-Theranostics For Cancer Applications. Nanotheranostics. 2017;1(1):1-22. DOI:10.7150/ntno.17109.
12. Lin Y, Yang Y, Yan J, Chen J, Cao J, Pu Y, Li L, He B. Redox/ATP switchable theranostic nanoparticles for real-time fluorescence monitoring of doxorubicin delivery. J Mater Chem B. 2018;6(14):2089-2103. DOI: 10.1039/c7tb03325g.
13. Peng H, Liu X, Wang G, Li M, Bratlie KM, Cochran E, Wang Q. Polymeric multifunctional nanomaterials for
theranostics. J Mater Chem B. 2015;3(34):6856-6870. DOI: 10.1039/c5tb00617a.
14. Fan W, Shen B, Bu W, Chen F, He Q, Zhao K, Zhang S, Zhou L, Peng W, Xiao Q, Ni D, Liu J, Shi J. A smart up conversion-based mesoporous silica nanotheranostic system for synergetic chemo-/radio-/photodynamic therapy and simultaneous MR/UCL imaging. Biomaterials. 2014;35(32):8992-9002. DOI: 10.1016/j.biomaterials.2014.07.024.
15. Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chem Rev. 2016;116(9):5338-431. DOI: 10.1021/acs.chemrev.5b00589.
16. Pitsillides CM, Joe EEK, Wei X, Anderson RR, Lin CP. Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys J. 2003;84(6):4023-32. DOI: 10.1016/S0006-3495(03)75128-5.
17. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chem Rev. 2016;116(4):2602-63. DOI: 10.1021/acs.chemrev.5b00346.
18. Webb JA, Bardhan R. Emerging advances in nanomedicine with engineered gold nanostructures. Nanoscale. 2014;6(5):2502-30. DOI: 10.1039/c3nr05112a.
19. Wu W, Wu Z, Yu T, Jiang C, Kim WS. Recent progress on magnetic iron oxide nanoparticles: Synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater. 2015;16(2):023501. DOI: 10.1088/1468-6996/16/2/023501.
20. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007;7(10):3065-70. DOI: 10.1021/nl071546n.
21. Kumar R, Kulkarni A, Nagesha DK, Sridhar S. In vitro evaluation of theranostic polymeric micelles for imaging and drug delivery in cancer. Theranostics. 2012;2(7):714-22. DOI:10.7150/thno.3927. Epub 2012 Jul 31. Yong KT, Wang Y, Roy I, Rui H, Swihart MT, Law WC, Kwak SK, Ye L, Liu J, Mahajan SD, Reynolds JL. Preparation of quantum dot/drug nanoparticle formulations for traceable targeted delivery and therapy. Theranostics. 2012;2(7):681-94. DOI: 10.7150/thno.3692.
22. Chen WH, Xu XD, Jia HZ, Lei Q, Luo GF, Cheng SX, Zhuo RX, Zhang XZ. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials. 2013;34(34):8798-807. DOI: 10.1016/j.biomaterials.2013.07.084.
23. Xiao Y, Hong H, Matson VZ, Javadi A, Xu W, Yang Y, Zhang Y, Engle JW, Nickles RJ, Cal W, Steeber DA, Gong S. Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics. 2012;2(8):757-68. DOI: 10.7150/thno.4756.
24. Rengan AK, Jagtap M, De A, Banerjee R, Srivastava R. Multifunctional gold coated thermo-sensitive liposomes for multimodal imaging and photo-thermal therapy of breast cancer cells. Nanoscale. 2014;6(2):916-23. DOI: 10.1039/c3nr04448c.
25. Daniel MC, Astruc D. Gold nanoparticles: Assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004;104(1):293-346. DOI: 10.1021/cr030698+.
26. Link S, El-Sayed MA. Shape and size dependence of radiative, non-radiative and photothermal properties of gold nanocrystals. Int. reviews in physical chemistry. 2000;19(3):409-53.
27. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1(3):325-7. DOI: 10.1002/sml.200400093.
28. Kumar R, Korideck H, Ngwa W, Berbeco RJ, Makrigiorgos GM, Sridhar S. Third generation gold nanoparticle optimized for radiation therapy. Transl Cancer Res. 2013;2(4):10.3978/j.issn.2218-676X.2013.07.02. DOI:10.3978/j.issn.2218-676X.2013.07.02. Lee SM, Kim HJ, Kim SY, Kwon MK, Kim S, Cho A, Yun M, Shin JS, Yoo KH. Drug-
loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. Biomaterials. 2014;35(7):2272-82. DOI: 10.1016/j.biomaterials.2013.11.068.

31. Heo DN, Yang DH, Moon HJ, Lee JB, Bae MS, Lee SC, Lee WJ, Sun IC, Kwon IK. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials. 2012;33(3):856-66. DOI: 10.1016/j.biomaterials.2011.09.064.

32. Hainfeld JF, Smilowitz HM, O’Connor MJ, Dilmahan FA, Slatkin DN. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine (Lond). 2013;8(10):1601-9. DOI: 10.2217/nmm.12.165.

33. Ruan S, He Q, Gao H. Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma. Nanoscale. 2015;7(21):9487-96. DOI: 10.1039/c5nr01408e.

34. Barabadi H. Nanobiotechnology: A promising scope of gold biotechnology. Cell Mol Biol (Noisy-le-grand). 2017;63(12):3-4. DOI: 10.14715/cmb.2017.63.12.2.

35. Boca-Farcău S, Potara M, Simon T, Juhem A, Baldeck P, Astilean S. Folic acid-conjugated, SERS-labeled silver nanotriangles for multimodal detection and targeted photothermal treatment on human ovarian cancer cells. Mol Pharm. 2014;11(2):391-9. DOI: 10.1021/mp400300m.

36. Mukherjee S, Chowdhry D, Kotcherlakota R, Patra S, B V, Bhadra MP, Sreedhar B, Patra CR. Potential theranostics application of bio-synthesized silver nanoparticles (4-in-1 system). Theranostics. 2014;4(3):316-35. DOI: 10.7150/thno.7819.

37. Rydz J, Sikorska W, Kylavskya M, Christova D. Polyester-based (bio)degradable polymers as environmentally friendly materials for sustainable development. Int J Mol Sci. 2014;16(1):564-96. DOI: 10.3390/ijms16010564.

38. Luk BT, Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces. 2014;6(24):21859-73. DOI: 10.1021/am5036225.

39. Wan Q, Liu M, Xu D, Mao L, Tian J, Huang H, Gao P, Deng F, Zhang X, Wei Y. Fabrication of aggregation induced emission active luminescent chitosan nanoparticles via a "one-pot" multicomponent reaction. Carbohydr Polym. 2016;152:189-195. DOI: 10.1016/j.carbpol.2016.07.026.

40. Andreiuk B, Reisch A, Lindecker M, Pollain G, Peyrière N, Goetz JG, Klymchenko AS. Fluorescent Polymer Nanoparticles for Cell Barcoding In Vitro and In Vivo. Small. 2017;13(38). DOI: 10.1002/smll.201701582.

41. Krasia-Christoforou T, Georgiou TK. Polymeric theranostics: using polymer-based systems for simultaneous imaging and therapy. J Mater Chem B. 2013;1(24):3002-3025. DOI: 10.1039/c3tb20191k.

42. Gobbo OL, Sjaastad K, Radomski MW, Volkov Y, Prina-Mello A. Magnetic Nanoparticles in Cancer Theranostics. Theranostics. 2015;5(11):1249-63. DOI: 10.7150/thno.11544.

43. Lo ST, Kumar A, Hsieh JT, Sun X. Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm. 2013;10(3):793-812. DOI: 10.1021/mp3005325.

44. Kopecek J, Kopecková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2010;62(2):122-49. DOI: 10.1016/j.addr.2009.10.004.

45) Nakamura H, Ettrych T, Chytíl P, Ohkubo M, Fang J, Ulbrich K, Maeda H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Release. 2014 Jan 28;174:81-7. doi: 10.1016/j.jconrel.2013.11.011.

46) Kuehne AJC. Conjugated Polymer Nanoparticles toward In Vivo Theranostics - Focus on Targeting, Imaging, Therapy, and the Importance of Clearance. Adv Biosyst. 2017 1(11):e1700100. DOI: 10.1002/adbi.201700100

47) Yuan J, Zhang H, Kaur H, Oupicky D, Peng F. Synthesis and characterization of theranostic poly(HPMA)-c(RGDyK)-DOTA-64Cu copolymer targeting tumor angiogenesis: tumor localization visualized by positron
emission tomography. Mol Imaging. 2013;12(3):203-12.
48. Jhaveri J, Raichura Z, Khan T, Momin M, Omri A. Chitosan Nanoparticles-Insight into Properties, Functionalization and Applications in Drug Delivery and Theranostics. Molecules. 2021;26(2):272. DOI: 10.3390/molecules2602072.
49. Loutfy SA, El-Din HM, Elberry MH, Allam NG, Hasanin MT, Abdellah AM. Synthesis, characterization and cytotoxic evaluation of chitosan nanoparticles: in vitro liver cancer model. Adv. Nat. Sci: Nanosci. Nanotechnol. 2016;7(3):035008.
50. Bondì ML, Botto C, Amore E, Emma MR, Augello G, Craparo EF, Cervello M. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. Int J Pharm. 2015;493(1-2):75-85. DOI: 10.1016/j.ijpharm.2015.07.055.
51. Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2015;93:27-36. DOI: 10.1016/j.ejpb.2015.03.003.
52. Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond). 2009;4(1):105-18. DOI: 10.2217/174355889.4.1.105.
53. Müller RH, Mäder K, Bas G, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-77. DOI: 10.1016/s0939-6411(00)00087-4.
54. Kuang Y, Zhang K, Cao Y, Chen X, Wang K, et al. (2017). Hydrophobic IR-780 Dye Encapsulated in cRGD-Conjugated Solid Lipid Nanoparticles for NIR Imaging-Guided Photothermal Therapy. ACS Appl. Mater. Interfaces. 2017;9:12217–12226. DOI: 10.1021/acsami.6b16705
55. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-72. DOI: 10.1016/j.addr.2003.12.002.
56. Bae KH, Lee JY, Lee SH, Park TG, Nam YS. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Adv Healthc Mater. 2013;2(4):576-84. DOI: 10.1002/adhm.201200338.
57. Videira, MA, Botelho MF, Santos AC, Gouveia LF et al. 2002. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002;10:607–613. DOI: 10.1080/106118602100054933
58. Silva CO, Pinho JO, Lopes JM, Almeida A J et al. (2019). Current trends in cancer nanotheranostics: Metallic, polymeric, and lipid-based systems. Pharmaceuticals. 2019;11:22. DOI: 10.3390/pharmaceutics11010022
59. Luk BT, Fang RH, Zhang L. Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics. 2012;2(12):1117-26. DOI: 10.7150/thno.4381.
60. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052-1063. DOI: 10.1016/j.addr.2010.08.004.
61. Yue X, Dai Z. Liposomal Nanotechnology for Cancer Theranostics. Curr Med Chem. 2018;25(12):1397-1408. DOI: 10.2174/09298673246661703061053.
62. Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Kann B, Dijk WJ, Griffin AM, Storm G, Fayad ZA, Mulder WJ. Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano. 2011;5(6):4422-33. DOI: 10.1021/nn103336a.
63. Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics. 2016;6(9):1336-52. DOI: 10.7150/thno.15464.
64. Ichihara H, Okumura M, Tsujimura K, Matsumoto Y. Theranostics with hybrid liposomes in an orthotopic graft model mice of breast cancer. Anticancer Res. 2018;38(10):5645-5654. DOI: 10.21873/anticancerres.12900.
65. Albuquerque J, Moura CC, Sarmento B, Reis S. Solid Lipid Nanoparticles: A potential multifunctional approach towards rheumatoid arthritis theranostics. Molecules. 2015;20(6):11103-18. DOI: 10.3390/molecules20061103.
66. Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci. 2015;3(7):923-36. DOI: 10.1039/c4bm00427b.

67. Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. J Drug Target. 2007;15(9):553-84. DOI: 10.1080/10611860701538586.

68. Kumar R, Kulkarni A, Nagesha DK, Sridhar S. In vitro evaluation of theranostic polymeric micelles for imaging and drug delivery in cancer. Theranostics. 2012;2(7):714-22. DOI: 10.7150/thno.3927.

69. Liu Z, Liang XJ. Nano-carbons as theranostics. Theranostics. 2012;2(3):235-7. DOI: 10.7150/thno.4156.

70. Mi Y, Liu Y, Feng SS. Formulation of Docetaxel by folic acid-conjugated d-a-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011;32(16):4058-66. DOI: 10.1016/j.biomaterials.2011.02.022.

71. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003;100(10):6039-44. DOI: 10.1073/pnas.0931428100.

72. Scott RW, Wilson OM, Crook RM. Synthesis, characterization, and applications of dendrimer-encapsulated nanoparticles. The Journal of Physical Chemistry B. 2005;109(2):692-704. DOI: 10.1021/jp0469665.

73. Sk UH, Kojima C. Dendrimers for theranostic applications. Biomol Concepts. 2015;6(3):205-17. PMID: 26136305.

74. Saad M, Garbuzenko OB, Ber E, Chandra P, Khandare JJ, Pozharov VP, Minko T. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release. 2008;130(2):107-14. DOI: 10.1016/j.jconrel.2008.05.024.

75. Taratula O, Schumann C, Naleway MA, Pang AJ, Chon KJ, Taratula O. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Mol Pharm. 2013;10(10):3946-58. DOI: 10.1021/mp400397t.

76. Liu Z, Robinson JT, Tabakman SM, Yang K, Dai H. Carbon materials for drug delivery & cancer therapy. Materials today. 2011;14(7-8):316-23. DOI.org/10.1016/S1369-7021(11)70161-4.

77. Loh KP, Bao Q, Eda G, Chhowalla M. Graphene oxide as a chemically tunable platform for optical applications. Nat Chem. 2010;2(12):1015-24. DOI: 10.1038/nchem.907.

78. Elhissi AM, Ahmed W, Hassan IU, Dhanak VR, D’Emanuele A. carbon nanotubes in cancer therapy and drug delivery. J Drug Deliv. 2012;2012:837327. DOI: 10.1155/2012/837327.

79. Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials. 2012;33(12):3494-501. DOI: 10.1016/j.biomaterials.2012.01.036.

80. d’Angelo M, Castelli V, Benedetti E, Antonosante A, Catanesi M, Dominguez-Benot R, Pitari G, Ippoliti R, Cimini A. Theranostic nanomedicine for malignant gliomas. Front Bioeng Biotechnol. 2019;7:325. DOI: 10.3389/fbioe.2019.00325.

81. Chen WH, Xu XD, Jia HZ, Lei Q, Luo GF, Cheng SX, Zhuo RX, Zhang XZ. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials. 2013;34(34):8798-807. DOI: 10.1016/j.biomaterials.2013.07.084.

82. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, Yang VC. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008 Feb;29(4):487-96. doi: 10.1016/j.biomaterials.2007.08.050.

83. Shuhendier AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater. 2012;1(5):600-8. DOI: 10.1002/adhm.201200006.

84. Pan J, Liu Y, Feng SS. Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond). 2010;5(3):347-60.
DOI: 10.2217/nnm.10.13.
85. Chandrasekharan P, Maity D, Yong CX, Chuang KH, Ding J, Feng SS. Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials. 2011;32(24):5663-72. DOI: 10.1016/j.biomaterials.2011.04.037.
86. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update. 2011;14(3):150-63. DOI: 10.1016/j.drup.2011.01.003.
87. Singh RP, Sharma G, Sonali, Singh S, Kumar M, Pandey BL, Koch B, Muthu MS. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016;141:429-442. DOI: 10.1016/j.colsurfb.2016.02.011.
88. Robinson JT, Welsher K, Tabakman SM, Sherlock SP, Wang H, Luong R, Dai H. High performance in vivo near-infrared (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res. 2010;3(11):779-793.

DOI: 10.1007/s12274-010-0045-1.
89. Chen Z, Ma L, Liu Y, Chen C. Applications of functionalized fullerenes in tumor theranostics. Theranostics. 2012;2(3):238-50. DOI: 10.7150/thno.3509.
90. Yang M, Meng J, Cheng X, Lei J, Guo H, Zhang W, Kong H, Xu H. Multiwalled carbon nanotubes interact with macrophages and influence tumor progression and metastasis. Theranostics. 2012;2(3):258-70. DOI: 10.7150/thno.3629.
91. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update. 2011;14(3):150-63. DOI: 10.1016/j.drup.2011.01.003.
92. Singh RP, Sharma G, Sonali, Singh S, Kumar M, Pandey BL, Koch B, Muthu MS. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016;141:429-442. DOI: 10.1016/j.colsurfb.2016.02.011.
93. Robinson JT, Welsher K, Tabakman SM, Sherlock SP, Wang H, Luong R, Dai H. High performance in vivo near-infrared (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res. 2010;3(11):779-793.

DOI: 10.1007/s12274-010-0045-1.
89. Chen Z, Ma L, Liu Y, Chen C. Applications of functionalized fullerenes in tumor theranostics. Theranostics. 2012;2(3):238-50. DOI: 10.7150/thno.3509.
90. Yang M, Meng J, Cheng X, Lei J, Guo H, Zhang W, Kong H, Xu H. Multiwalled carbon nanotubes interact with macrophages and influence tumor progression and metastasis. Theranostics. 2012;2(3):258-70. DOI: 10.7150/thno.3629.
91. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update. 2011;14(3):150-63. DOI: 10.1016/j.drup.2011.01.003.
92. Singh RP, Sharma G, Sonali, Singh S, Kumar M, Pandey BL, Koch B, Muthu MS. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016;141:429-442. DOI: 10.1016/j.colsurfb.2016.02.011.
93. Robinson JT, Welsher K, Tabakman SM, Sherlock SP, Wang H, Luong R, Dai H. High performance in vivo near-infrared (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res. 2010;3(11):779-793.

DOI: 10.1007/s12274-010-0045-1.
89. Chen Z, Ma L, Liu Y, Chen C. Applications of functionalized fullerenes in tumor theranostics. Theranostics. 2012;2(3):238-50. DOI: 10.7150/thno.3509.
90. Yang M, Meng J, Cheng X, Lei J, Guo H, Zhang W, Kong H, Xu H. Multiwalled carbon nanotubes interact with macrophages and influence tumor progression and metastasis. Theranostics. 2012;2(3):258-70. DOI: 10.7150/thno.3629.
91. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update. 2011;14(3):150-63. DOI: 10.1016/j.drup.2011.01.003.
92. Singh RP, Sharma G, Sonali, Singh S, Kumar M, Pandey BL, Koch B, Muthu MS. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016;141:429-442. DOI: 10.1016/j.colsurfb.2016.02.011.
93. Robinson JT, Welsher K, Tabakman SM, Sherlock SP, Wang H, Luong R, Dai H. High performance in vivo near-infrared (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res. 2010;3(11):779-793.